Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421603
Status:
COMPLETED
Last Update Posted:
2019-04-24
First Post:
2007-01-10
Brief Title:
A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence
Sponsor:
New York State Psychiatric Institute
Organization:
New York State Psychiatric Institute
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Study of Mixed Amphetamine Salts Adderall-XR and Topiramate for the Treatment of Cocaine Dependence
Status:
COMPLETED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TACT
Brief Summary:
The proposed protocol is a double-blind placebo-controlled outpatient study of the safety and efficacy of Adderall-XR ER-MAS and topiramate in the treatment of cocaine dependence Since both of these medications have independently shown promise in helping with cocaine abuse we are proposing that together they may be even more successful in the treatment of cocaine abuse We plan to enroll 120 subjects in a 14-week trial The primary objective of the study is to determine the efficacy of ER-MAS and topiramate in promoting cocaine abstinence among cocaine-dependent patients This study includes free treatment for cocaine dependence that includes medication
Detailed Description:
Specific Aim 1 To determine the efficacy of ER-MAS and topiramate in promoting cocaine abstinence among cocaine-dependent patients
Primary Hypothesis The proportion of participants achieving sustained cocaine abstinence via urine toxicology for three consecutive weeks during the study will be significantly greater for the combined pharmacotherapies group compared to the placebo group
Hypothesis 2 The proportion of urine samples negative for cocaine metabolites will be greater in the combined pharmacotherapies group compared to the placebo group
Hypothesis 3 The pattern of cocaine use amount of cocaine used per day in dollars and the number of using days per week as measured by the time-line follow-back method will show a greater reduction in use for the combined pharmacotherapies group compared to the placebo group
Specific Aim 2 To determine the effect of ER-MAS and topiramate on cocaine craving among cocaine-dependent patients
Hypothesis 4 Cocaine craving symptoms will be reduced to a greater degree in the combined pharmacotherapies group compared to the placebo group
Specific Aim 3 To explore a set of related secondary outcomes treatment retention global functioning HIV risk behavior as well as moderators and mediators potentially reflective of mechanism of action
Primary Hypothesis The proportion of participants achieving sustained cocaine abstinence via urine toxicology for three consecutive weeks during the study will be significantly greater for the combined pharmacotherapies group compared to the placebo group
Hypothesis 2 The proportion of urine samples negative for cocaine metabolites will be greater in the combined pharmacotherapies group compared to the placebo group
Hypothesis 3 The pattern of cocaine use amount of cocaine used per day in dollars and the number of using days per week as measured by the time-line follow-back method will show a greater reduction in use for the combined pharmacotherapies group compared to the placebo group
Specific Aim 2 To determine the effect of ER-MAS and topiramate on cocaine craving among cocaine-dependent patients
Hypothesis 4 Cocaine craving symptoms will be reduced to a greater degree in the combined pharmacotherapies group compared to the placebo group
Specific Aim 3 To explore a set of related secondary outcomes treatment retention global functioning HIV risk behavior as well as moderators and mediators potentially reflective of mechanism of action
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DA022217 | NIH | None | httpsreporternihgovquickSearchR01DA022217 |